Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis

Neurology

Volumn 53, Issue 7, 1999, Pages 1397-1401

  Waubant, E ^a   Goodkin, D E ^a   Gee, L ^b   Bacchetti, P ^b   Sloan, R ^a   Stewart, T ^a   Andersson, P B ^a   Stabler, G ^c   Miller, K ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c British Biotechnology   (United Kingdom)

Author keywords

Inhibitor of metalloproteinase; Matrix metalloproteinase; MRI; MS

Indexed keywords

GADOLINIUM; GELATINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CARTILAGE DEGENERATION; CELL COMPARTMENTALIZATION; CONTRAST ENHANCEMENT; DRUG BLOOD LEVEL; EMBRYO DEVELOPMENT; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; MACROPHAGE ACTIVATION; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

EID: 0032693982     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.7.1397     Document Type: Article

References (32)

1. Hartung H-P, Reiners K, Archelos J, et al. Circulating adhesion molecules and tumor necrosis factor receptor in multiple sclerosis: correlation with magnetic resonance imaging. Ann Neurol 1995;38:186-193.
2. Mossner R, Fassbender K, Kuhnen J, Schwartz A, Hennerici M. Circulating L-selectin in multiple sclerosis patients with active, gadolinium-enhancing brain plaques. J Neuroimmunol 1996;65:61-65.
3. Giovannoni G, Lai M, Thorpe J, et al. Longitudinal study of soluble adhesion molecules in multiple sclerosis: correlation with gadolinium enhanced magnetic resonance imaging. Neurology 1997;48:1557-1565.
4. Welgus HG, Campbell EJ, Cury JD, et al. Neutral metalloproteinases produced by human mononuclear phagocytes. Enzymes profile, regulation, and expression during cellular development. J Clin Invest 1990;86:1496-1502.
5. Conca W, Willmroth F. Human T lymphocytes express a member of the matrix metalloproteinase gene family. Arthritis Rheum 1994;37:951-956.
6. Leppert D, Waubant E, Galardy R, Bunnett N, Hauser S. T cell gelatinases mediate basement membrane transmigration in vitro. J Immunol 1995;154:4379-4389.
7. Birkedal-Hansen H, Moore WGI, Bodden MK, et al. Metalloproteinases: a review. Crit Rev Oral Biol Med 1993;4:197-250.
8. Docherty AJP. The matrix metalloproteinases and their natural inhibitors: prospects for treating degenerative tissue diseases. TIBTECH 1992;10:200-207.
9. Lee MA, Palace J, Stabler G, Ford J, Gearing A, Miller K. Serum gelatinase B, TIMP-1 and TIMP-2 levels in multiple sclerosis: a longitudinal clinical and MRI study. Brain 1999; 122:191-197.
10. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-231.
11. Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46:907-911.
12. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
13. Woods RP, Mazziotta JC, Cherry SR. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992;16:620-633.
14. Woods RP, Mazziotta JC, Cherry SR. MRI-PET registration with automated algorithm. J Comput Assist Tomogr 1993;17: 536-546.
15. Goodkin DE, Rooney WD, Sloan R, et al. A serial study of new multiple sclerosis lesions and white matter from which they arise. Neurology 1998;51:1689-1697.
16. Uhm JH, Dooley NP, Oh LY, Yong VW. Oligodendrocytes utilize a matrix metalloproteinase, MMP-9, to extend processes along an astrocyte extracellular matrix. Glia 1998;22: 53-63.
17. Stüve O, Dooley NP, Uhm JH, et al. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863.
18. Proost P, Van Damme J, Opdenakker G. Leukocyte gelatinase B cleavage releases encephalitogens from human myelin basic protein. Biochem Biophys Res Commun 1993;192:1175-1181.
19. Chandler S, Coates R, Gearing A, Lury J, Wells G, Bone E. Matrix metalloproteinases degrade myelin basic protein. Neurosci Lett 1995;201:223-226.
20. Clements JM, Cossins JA, Wells GMA, et al. Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effect of a combined matrix metalloproteinase and tumor necrosis factor-alpha inhibitor. J Neuroimmunol 1997;74:85-94.
21. Gijbels K, Masure S, Carton H, Opdenakker G. Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders. J Neuroimmunol 1992;41:29-34.
22. Miller K, Ford J, Ward G, Gearing A, Palace J. Elevation of 92-kDa gelatinase in serum is associated with clinical relapse in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:225-226.
23. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain 1998; 121:2327-2334.
24. Gijbels K, Galardy R, Steinman L. Reversal of experimental autoimmune encephalomyelitis with a hydroxamate inhibitor of matrix metalloproteases. J Clin Invest 1994;94:2177-2182.
25. Maeda A, Sobel R. Matrix metalloproteinases in the normal human central nervous system, microglial nodules, and multiple sclerosis lesions. J Neuropathol Exp Neurol 1996;55:300-309.
26. Anthony DC, Ferguson B, Matyzack MK, Miller KM, Esiri MM, Perry VH. Differential matrix metalloproteinase expression in cases of multiple sclerosis and stroke. Neuropathol Appl Neurobiol 1997;23:406-415.
27. Leppert D, Waubant E, Burk MR, Oksenberg J, Hauser S. Interferon beta-1b inhibits gelatinase secretion and in vivo migration of human T-cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:244-250.
28. Stone LA, Frank JA, Albert PS, et al. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol 1995;37:611-619.
29. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
30. Pozzilli C, Bastianello S, Koudriavtseva T, et al. Magnetic resonance imaging changes with recombinant human interferon-beta-la: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-258.
31. Waubant E, Sloan R, Vermathen M, Rooney W, Weiner M, Goodkin D. A pilot study of the effect of weekly intramuscular (IM) 6.0 MIU interferon beta-la (IFNB-1a) on monthly gadolinium-enhanced (Gd+) brain MRI activity in patients with relapsing multiple sclerosis (MS). J Neurol 1998;245:385. Abstract.
32. Rosenberg GA, Dencoff JE, Correa N, Reiners M, Ford CC. Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632.